Skip to content
  • Home
  • More
    • Enterprise Services
    • Affiliate Program
    • Official Links
    • About
  • MachinaAI

    Login
    • Home
    • News
    • Dashboard
      My Dashboard Equity Dashboard Analyst Dashboard Large Companies Portfolio
    • Smart Reports

Simplify financial decision-making

Machinary offers a modular and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

 

Register now and get free Credits

Sign up

Know the Market. Stay Ahead.

Market Insights & Analytics.

Gain access to a comprehensive retail platform with real-time updates on the stock market and critical financial metrics. Leverage advanced tools for better decision-making:

  • Overview of stock market data:Stay updated with the latest market trends and performance.
  • Monitor AI-based predictions:Access detailed company analytics.
  • Sentiment Analysis:Understand market emotions with AI-driven sentiment insights.
  • Relevance Score:Prioritize information that matters most.
  • Chatbot Integration:Get instant answers and insights through smart AI.
  • Customizable Widgets:Add or remove widgets to tailor your dashboard.
Sign up for early access

Stay Informed. Act Strategically.

Real-Time News Portal.

Unlock actionable insights with categorized, real-time news updates tailored to your needs. Stay ahead in the market with a reliable flow of information:

  • People:Explore updates about key influencers and market leaders.
  • Public Companies:Stay informed on listed corporations and their market activities.
  • Non-Public Companies:Gain insights into the operations of private enterprises.
  • Countries:Understand regional economic shifts and geopolitical trends.
  • Commodities:Monitor pricing and trends for critical commodities like oil, gold, and more.
  • Currencies:Keep track of currency fluctuations and forex market developments.
Sign up for early access

Modular Power. Limitless Potential.

Machinary empowered by MachinaCore

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Reaching new heights together.

Stay tuned for what’s coming next.

Exciting innovations are on the horizon! Stay tuned as we unveil new advancements designed to empower smarter decisions and greater success in the fast-paced world of finance.

Sign up for early access

Explore tailored enterprise solutions - that make an impact.

Exciting innovations are on the horizon! Stay tuned as we unveil new advancements designed to empower smarter decisions and greater success in the fast-paced world of finance.

Get in touch

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

  • Home
  • News
  • Dashboard
  • About us
  • Contact

Address

  • MachinaLabs AG
  • Viaduktstrasse 42
  • 4051 Basel
  • Switzerland

  • info@machinalabs.net
  • machinalabs.net

Newsletter

Subscription successful!

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Predefined Themes

Layout settings

Choose the font family that fits your app.

Choose the gray shade for your app.

Choose the border radius factor for your app.

Save settings

Welcome to Machina, a platform to connect with the social world

Forgot Password?

Don't have an account?Sign Up

Welcome to Machina, a platform to connect with the social world

Already have an account?Login

  • Home
  • More
    • Enterprise Services
    • Affiliate Program
    • Official Links
    • About

Pharmaceutical Investors Favor Obesity Treatments Over Cancer Drugs

  1. Home
  2. Bobs-News Categories Company News
  3. Pharmaceutical Investors Favor Obesity Treatments Over Cancer Drugs
  • bob
  • 2024-01-11
  • Company News
  • Europe
  • Investment Insights
  • Market Updates

Pharmaceutical giants Eli Lilly and Novo Nordisk have seen their value more than triple in less than three years. Their combined corporate value, which consists of market capitalization plus net debt, was around $360 billion at the height of the COVID-19 pandemic in February 2021. It has since grown to a trillion dollars.

The rapid rise of these two companies is largely attributed to their leading position in the business of novel therapies for the treatment of obesity. Eli Lilly’s shares alone increased by three-quarters in the past year, making it the first drug manufacturer to reach a market capitalization of over $500 billion. The Danish competitor, Novo Nordisk, saw a 50% increase in 2023.

Other pharmaceutical companies have not been nearly as successful recently. Roche, a Swiss pharmaceutical manufacturer, has been particularly disappointing, falling to sixth place in terms of corporate value. In early 2021, when the company was largely favored by the pandemic due to its SARS-CoV-2 detection tests, it was in second place. Novartis slipped from fifth to ninth place during the same period.

According to analysts at the securities firm Stifel, there is a paradigm shift in the pharmaceutical industry. Gone are the days when investors preferred companies that would develop as specific treatments as possible against cancer diseases in advance. Such therapies can indeed be marketed at high prices because they target a manageable circle of patients. However, this approach also limits their sales potential. Nowadays, investors favor companies that present solutions for common chronic ailments such as obesity, diabetes, chronic obstructive pulmonary disease (smoker’s lung), or asthma.

As for the new weight loss injections, it remains to be seen how far governments and health insurers will reimburse patients for their costs. In the US, it is currently more likely that wealthy women from Beverly Hills, whose body weight is almost normal, would resort to the medication rather than severely overweight poor people from states like Mississippi or Alabama. Patients from California and other wealthy coastal regions could pay for the treatment out of their own pocket.

According to calculations by analysts at the investment bank Goldman Sachs, the windfall that investors expect from the marketing of the new obesity therapy is largely taken into account in Eli Lilly’s stock market valuation. They also point to the risk that insurers in price negotiations could rather orient themselves towards the approaches in Europe than the current American list price. Novo Nordisk charges about $1,000 per month for the Wegovy weight loss injection in the US. In Europe, according to Goldman Sachs, it costs between $190 and $330.

For market observers at Baader Europe, the time has come to build positions in the shares of previously shunned European drug manufacturers. Given that the industry-wide price-earnings ratio for 2024 is currently only at 16, these are “ridiculously cheap” to have. Roche, Sanofi, and Bayer are on the securities firm’s recommendation list. The securities of the French and German pharmaceutical companies came under strong selling pressure last year. Whether the resulting price losses can already be made up for in 2024 is not certain.



This News Article was automatically generated by Bob the Bot (AI)

Information Details
Geography Europe
Countries πŸ‡ΊπŸ‡Έ πŸ‡©πŸ‡° πŸ‡¨πŸ‡­
Sentiment neutral
Relevance Score 1
People Dominik Feldges
Companies Goldman Sachs, Baader Europe, Sanofi, Novartis, Roche, Eli Lilly, Novo Nordisk, Bayer, Stifel
Currencies US Dollar
Securities Novartis, Roche, Eli Lilly, Novo Nordisk, Bayer

Leave a Reply Cancel reply

You must be logged in to post a comment.



Β MachinaTrader

A new era of trading and data analytics

Everything in one place. Highly reliable, ultra-scalable and blazingly fast!

Related Links

News Blog
Forums
FAQ
About
Privacy Policy (DSGVO/GDPR)

Our Partners
sygnal logo 40
bullishtimes logo white
Β© 2023 MachinaLabs AG. All Rights Reserved.
People Who like this post
  • img
img